Business Context and Reporting Period
This Form 8-K Current Report was filed by Aethlon Medical, Inc. (AEMD) on October 22, 2025. The report addresses a regulatory notice received on October 16, 2025, regarding the company's compliance with Nasdaq Capital Market listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory action: the closing bid price for the company's common stock was below $1.00 per share for 30 consecutive business days.
Material Changes
- Delisting Notice: The company received a notification from Nasdaq stating it failed to meet the Minimum Bid Price Requirement (Rule 5550(a)(2)) due to the stock price remaining below $1.00 for 30 consecutive business days.
- Reverse Stock Split: To regain compliance, the company implemented a 1-for-10 reverse stock split. This action became effective on October 16, 2025, with trading commencing on October 20, 2025.
- Appeal Filed: The company has filed a request for a hearing before the Nasdaq Hearings Panel. This request automatically stays any suspension or delisting action pending the panel's decision.
Outlook, Risks, and Management Commentary
Management is actively monitoring the closing bid price of its common stock and will evaluate additional actions as appropriate to maintain its listing. The filing includes standard forward-looking statements cautioning that actual results may differ due to risks, including the uncertainty of regaining compliance with Nasdaq requirements and the potential for delisting if compliance is not achieved.
Investor Verification Checklist
- Verify the current trading price of AEMD post-split to confirm if it has sustained a bid price above $1.00.
- Monitor the status of the hearing request filed with the Nasdaq Hearings Panel.
- Review the company's most recent Form 10-K and 10-Q for detailed financial health and liquidity positions not included in this 8-K.
- Check for any subsequent announcements regarding the outcome of the Nasdaq hearing or further corporate actions.